# Phase 1, First in Human, Open-Label, Dose-Escalation Study of 609A

> **NCT03950297** · PHASE1 · UNKNOWN · sponsor: **Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.** · enrollment: 24 (estimated)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** 609A

## Key facts

- **NCT ID:** NCT03950297
- **Lead sponsor:** Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-05-01
- **Primary completion:** 2020-10-24
- **Final completion:** 2022-05-24
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2020-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03950297

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03950297, "Phase 1, First in Human, Open-Label, Dose-Escalation Study of 609A". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03950297. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*